The MedicalXpress report highlights influencer-driven promotion of injectable peptides for fat loss and recovery but underplays how this exploits platform algorithms to normalize unstudied compounds among vulnerable users. While approved peptides like GLP-1 agonists rest on large-scale RCTs (e.g., STEP trials, n>2000, industry-funded yet with transparent endpoints showing gastrointestinal risks), gray-market versions lack any equivalent evidence, relying instead on anecdotal claims that mask contamination documented in FDA seizure reports. Observational data from poison control centers (retrospective cohorts, n~500 cases) reveal immune and injection-site harms absent from influencer disclosures, a gap the source misses amid its focus on marketing tactics. Affiliate structures convert follower admiration into revenue without medical oversight, amplifying emotional trust violations; young users face heightened exposure due to algorithmic immersion, a pattern seen in prior supplement scandals. Synthesizing FDA compounding warnings and peer-reviewed safety reviews underscores that personal health risks—nausea to anaphylaxis—stem directly from absent RCTs and hidden incentives, demanding user-level caution over slow enforcement.